Greg, I realize that Gerald has stated numerous times we would up list on strength. Everybody here believes that or we wouldn't be long. That said, with regards to trading on "Margin" The risks are greater. I see nothing but upside right now with this stock. We should rocket upwards in less than a month and never look back. After the additional shares and up list, one would think some of that upside will have been exhausted. I'll re-emphasis some. Plus we can predict how the market would react to up listing from an RS will react immediately. I do believe we will move higher as revenue for LymPro will be great and of course MANF. Margin trading is scary. I would rather margin trade right this second in all honest as I see no downside...However, I'll more than likely margin trade after the up list as I am so confident in this company and management.
I do realize I'm speaking on both sides of my mouth. To sum this up, I agree with warp and I agree with Dave regarding margin trading AMBS lol
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links